SCHEMBL24316985

SCHEMBL24316985

COc1cc(O)cnc1OCc1ccc(Cl)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MRGPRX4 Q96LA9 2/20 0.49
SCN9A Q15858 2/20 0.48
NPC1 O15118 4/20 0.47
RAB9A P51151 4/20 0.47
MEN1 O00255 3/20 0.47
KMT2A Q03164 3/20 0.47
SMN1; SMN2 Q16637 3/20 0.47
ALDH1A1 P00352 3/20 0.47
NFKB1 P19838 1/20 0.47
NFKB2 Q00653 1/20 0.47
RELA Q04206 1/20 0.47
HDAC1 Q13547 1/20 0.46
HDAC8 Q9BY41 1/20 0.46
HDAC6 Q9UBN7 1/20 0.46
SCN5A Q14524 1/20 0.46
FNTA P49354 1/20 0.45
FNTB P49356 1/20 0.45
PLK1 P53350 1/20 0.45
MAPT P10636 5/20 0.43
LMNA P02545 3/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21327653 0.87 CSF1R (0.54) NPC1RAB9ASMN1; SMN2ALDH1A1LMNA
SCHEMBL24316420 0.87 MAOB (0.45) SCN9ANPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL24316419 0.85 PDGFRB (0.49) MRGPRX4NPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL24316986 0.85 KDM4E (0.50) MEN1KMT2AMAPTLMNACYP1A2
SCHEMBL24316988 0.82 CHRM4 (0.41) SCN9ANPC1RAB9AALDH1A1MAPT
SCHEMBL24316418 0.81 CSF1R (0.41) CSF1R
SCHEMBL24316987 0.78 DHODH (0.38) SCN9ANPC1RAB9ALMNACSF1R
SCHEMBL19461724 0.77 CSF1R (0.46) NPC1RAB9ASMN1; SMN2ALDH1A1MAPT
SCHEMBL324131 0.75 CYP3A4 (0.46) ALDH1A1NFKB1NFKB2RELAMAPT
SCHEMBL21357210 0.75 CSF1R (0.50) MRGPRX4SCN9ANPC1RAB9AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240092774-A1 HETEROAROMATIC COMPOUNDS AND USES THEREOF HUTCHISON MEDIPHARMA LIMITED (CN) 2024-03-21 US disclosed
EP-4214198-A1 HETEROAROMATIC COMPOUNDS AND USES THEREOF Hutchison Medipharma Limited (CN) 2023-07-26 EP disclosed
CN-116323582-A Heteroaromatic ring compounds and uses thereof 和记黄埔医药(上海)有限公司 2023-06-23 CN disclosed
WO-2022057895-A1 HETEROAROMATIC COMPOUNDS AND USES THEREOF HUTCHISON MEDIPHARMA LIMITED (CN) 2022-03-24 WO disclosed
WO-2022057895-A1 HETEROAROMATIC COMPOUNDS AND USES THEREOF HUTCHISON MEDIPHARMA LIMITED (CN) 2022-03-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240092774-A1 HETEROAROMATIC COMPOUNDS AND USES THEREOF CYP2D6, CYP3A7, CYP2F1 MRGPRX4 912/4885SCN9A 2462/4885NPC1 283/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.